Eli Lilly plans Mounjaro launch for weight loss and diabetes in India by 2025

Eli Lilly plans to launch Mounjaro, a weekly injection for weight loss and diabetes management, in India by 2025, pending regulatory approvals. The drug, known as Tirzepetide, aims to address obesity and diabetes. The company has not yet set a price for Mounjaro. Eli Lilly emphasizes the drug's effectiveness and its potential to improve overall health, while also addressing safety concerns raised in reports about side effects. Mounjaro is not recommended for pregnant women or those with certain rare conditions. Eli Lilly stresses the importance of recognizing obesity as a serious health issue, not just a cosmetic concern.